Back to Search Start Over

Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma

Authors :
Kimitoshi Kohno
Yasuyuki Sasaguri
Toshiyuki Nakayama
Yoshikazu Harada
Hirotsugu Noguchi
Yuichiro Kawatsu
Hiroshi Hijioka
Hidetaka Uramoto
Akihiko Miyawaki
Tomoko Kimura
Sohsuke Yamada
Hiroto Izumi
Akihiro Kuma
Ryoichi Oya
Shohei Kitada
Ke-Yong Wang
Source :
Tumour Biology
Publication Year :
2015
Publisher :
Springer Netherlands, 2015.

Abstract

The polypeptide N-acetylgalactosaminyltransferase (GalNAc-Ts) family of enzymes regulates the critical initial steps of mucin-type O-glycosylation. Among GalNAc-Ts that may significantly influence cancer biology, thus affecting cell differentiation, adhesion, invasion, and/or metastasis, GalNAc-T3 exhibits a high expression in several human cancers, closely associated with tumor progression and a poor prognosis. However, the expression pattern of GalNAc-T3 in oral squamous cell carcinoma (OSCC) remains obscure. Since postoperative recurrence of even early stage OSCC (ESOSCC) occurs at an early phase, significantly affecting their clinical course and worse outcome, the identification of clinically significant accurate biomarkers is needed. Therefore, we investigated the correlation between the immunohistochemical GalNAc-T3 expression and various clinicopathological characteristics and recurrence using 110 paraffin-embedded tumor samples obtained from patients with surgically resected ESOSCC (T1–2N0). Recurrence was recognized in 37 of 110 (33.6 %) patients. The GalNAc-T3 expression was considered to be strongly positive when 20 % or more of the cancer cells showed positive cytoplasmic staining. Consequently, a strong expression of GalNAc-T3 was observed in 40 patients (36.4 %), showing a close relationship to poor differentiation, the presence of lymphatic and vascular invasion, and recurrence. Univariate and multivariate analyses further demonstrated that the patients with a strong GalNAc-T3+ status had markedly lower disease-free survival (DFS) rates, especially within the first 2 years postoperatively. Therefore, GalNAc-T3 might play a role in the pathogenesis of ESOSCC recurrence, and its immunohistochemical detection potentially predicts a shorter DFS and may be a useful parameter for providing clinical management against ESOSCC in the early postoperative phase. Electronic supplementary material The online version of this article (doi:10.1007/s13277-015-3928-7) contains supplementary material, which is available to authorized users.

Details

Language :
English
ISSN :
14230380 and 10104283
Volume :
37
Issue :
1
Database :
OpenAIRE
Journal :
Tumour Biology
Accession number :
edsair.doi.dedup.....a553895e56c2e7f718ab777fa1f5cfcc